EUVIMEDEUVIMED entdecken
Leitlinie

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2

Lyudmila Bazhenova iD, Nofisat Ismaila iD, Fawzi Abu Rous iD, Krishna Alluri iD, Janet Freeman-Daily iD, Balazs Halmos iD, Narinder Malhotra, Kristen A Marrone, Sonam Puri iD, Angel Qin iD, Natasha B Leighl iD

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco-24-02133 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Lyudmila Bazhenova und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego Moores Cancer Center, San Diego, CA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See the Appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNeoplasm StagingMedical Oncology

Autor:innen und Institutionen

  • University of California San Diego Moores Cancer Center, San Diego, CA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI.
  • Texas Oncology, San Antonio, TX.
  • The ROS1ders, Seattle, WA.
  • Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.

ORCID-Profile: Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, Krishna Alluri, Janet Freeman-Daily, Balazs Halmos, Sonam Puri, Angel Qin, Natasha B Leighl

Zitieren

APA

Bazhenova, L., Ismaila, N., Abu Rous, F., Alluri, K., Freeman-Daily, J., Halmos, B., Malhotra, N., Marrone, K. A., Puri, S., Qin, A., & Leighl, N. B. (2024). Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02133

Vancouver

Bazhenova L, Ismaila N, Abu Rous F, Alluri K, Freeman-Daily J, Halmos B, et al. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2. Journal of Clinical Oncology. 2024. doi:10.1200/jco-24-02133

BibTeX
@article{Bazhenova2024,
  author = {Bazhenova, Lyudmila and Ismaila, Nofisat and Abu Rous, Fawzi and Alluri, Krishna and Freeman-Daily, Janet and Halmos, Balazs and Malhotra, Narinder and Marrone, Kristen A and Puri, Sonam and Qin, Angel and Leighl, Natasha B},
  title = {Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco-24-02133}
}
Kostenlos starten →